Phase III trial of remestemcel-L (MSC-100 mesenchymal stem cells) in adults with liver/gut graft-versus-host disease.

Trial Profile

Phase III trial of remestemcel-L (MSC-100 mesenchymal stem cells) in adults with liver/gut graft-versus-host disease.

Planning
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2015

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Mesoblast
  • Most Recent Events

    • 12 Feb 2015 According to a Mesoblast media release, JCR has filed for Japanese regulatory approval for JR-031 (Remestemcel-L) in acute graft-versus-host disease.
    • 15 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top